Telix Pharmaceuticals · expansion
Telix Agrees $1.65 Billion ITM Acquisition to Add Isotope Production and Therapeutics
Telix Pharmaceuticals has agreed to acquire ITM for US$1.65 billion upfront, adding profitable radioisotope manufacturing and a late-stage therapeutics pipeline, but the transaction has not yet closed.
Has Telix completed the ITM acquisition?
No. Telix expects the transaction to close by the end of 2026, subject to Telix shareholder approval, regulatory approvals and other closing conditions.
Orbitrum Investor Impact
How much is Telix paying for ITM?
The upfront consideration is US$1.65 billion on a cash-free, debt-free basis, with ITM shareholders expected to receive about US$1.25 billion in Telix shares after adjustments. Up to another US$700 million is contingent on ITM-11 regulatory approvals and sales milestones.
Why does the ITM deal matter for Telix?
ITM adds a profitable commercial radioisotope manufacturing business that generated US$273 million of revenue in 2025, strengthens Telix's isotope supply and adds the Phase 3-completed ITM-11 cancer therapy to its pipeline.
Will the acquisition dilute existing Telix shareholders?
Yes. Telix plans to issue 105.8 million shares for the closing consideration, leaving existing Telix shareholders with about 76.3% of the enlarged company and ITM shareholders with about 23.7%.
What should Telix investors watch next?
Telix expects an extraordinary shareholder meeting in November 2026 and is targeting completion by year-end if the required shareholder, regulatory and other approvals are obtained.
Sources
- Telix Pharmaceuticals — Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
- Reuters — Australia's Telix Pharma agrees to buy Germany's ITM Isotope for about $1.65 billion
Original signal: Reuters ↗
See more Orbitrum in Google
Add Orbitrum as a Preferred Source to make our research more likely to appear for you in Google Search.